Cash, cash equivalents and investments in marketable debt securities totaled $96M as of December 31, 2023, compared to $118.4M as of June 30, 2023. “2024 is an exciting year of execution and milestones across our pipeline, with RZ358 continuing to demonstrate benefit to patients with hypoglycemia resulting from varying causes of hyperinsulinism, and in different indications,” said Nevan Charles Elam, CEO and founder of Rezolute. “We recently initiated sunRIZE, a global, pivotal, Phase 3 clinical study in patients with congenital hyperinsulinism, and we also continue to see favorable outcomes from our Expanded Access Program with RZ358, in patients with tumor-associated hyperinsulinism caused by insulinomas, for which we are evaluating a potential development program. Additionally, we completed enrollment in the Phase 2 study of RZ402 in patients with diabetic macular edema and look forward to reporting topline data from that program in the second quarter of 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RZLT:
- Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
- Is RZLT a Buy, Before Earnings?
- Rezolute Receives Innovation Passport, Appoints New CFO
- Rezolute appoints Evans as Chief Financial Officer
- Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer